Arvinas Estrogen Receptor, Inc.
Clinical trials sponsored by Arvinas Estrogen Receptor, Inc., explained in plain language.
-
New hope for advanced breast cancer: experimental drug shows promise in early trial
Disease control CompletedThis study tested an experimental drug called ARV-471, alone or with another drug (palbociclib), in 217 adults with a common type of advanced breast cancer (ER+/HER2-) that had stopped responding to prior hormone therapy and chemotherapy. The main goals were to check safety and s…
Phase: PHASE1, PHASE2 • Sponsor: Arvinas Estrogen Receptor, Inc. • Aim: Disease control
Last updated May 26, 2026 10:28 UTC
-
New combo therapy shows promise in advanced breast cancer trial
Disease control CompletedThis early-phase trial tested a new combination of two drugs, ARV-471 and everolimus, in 32 people with a certain type of advanced breast cancer (ER+/HER2-). The main goals were to find the safest dose and check for side effects. The study is now complete, and results will help g…
Phase: PHASE1 • Sponsor: Arvinas Estrogen Receptor, Inc. • Aim: Disease control
Last updated May 26, 2026 10:23 UTC